Boundless Bio (BOLD) Retained Earnings (2023 - 2026)
Boundless Bio (BOLD) posted quarterly Retained Earnings of -$273.2 million for Q1 2026, down 25.79% year-over-year from -$368.2 million in Q1 2025, and down 5.22% quarter-over-quarter from -$259.7 million in Q4 2025.
Boundless Bio (BOLD) Retained Earnings (2023 - 2026) Analysis & Trends
Boundless Bio (BOLD) has reported Retained Earnings for 4 consecutive years, with -$273.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 25.79% year-over-year to -$273.2 million; the TTM figure through Mar 2026 stood at -$273.2 million (down 25.79% YoY), while the FY2025 annual figure was -$259.7 million, down 214702.48% from the prior year.
- Retained Earnings eased to -$273.2 million in Q1 2026 per BOLD's latest filing, from -$259.7 million in the prior quarter.
- Across five years, Retained Earnings topped out at $355.6 million in Q2 2025 and bottomed at -$273.2 million in Q1 2026.
- Historically, Retained Earnings has averaged -$113.1 million across 4 years, with a median of -$176.8 million in 2024.
- On a YoY basis, Retained Earnings climbed as much as 311.02% in 2025 and fell as far as 1034185.71% in 2025.
- Boundless Bio's Retained Earnings stood at -$136.1 million in 2023, then jumped by 100.09% to $121000.0 in 2024, then sank by 214702.48% to -$259.7 million in 2025, then fell by 5.22% to -$273.2 million in 2026.
- Business Quant data shows BOLD's Retained Earnings at -$273.2 million in Q1 2026, -$259.7 million in Q4 2025, and -$246.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 4.38 Bn |
| 10 | Boundless Bio | 66.72 Mn | 66.72 Mn | - | 362.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 362.92 Mn |
| Mar 31, 2026 | -273.22 Mn |
| Dec 31, 2025 | -259.67 Mn |
| Sep 30, 2025 | -246.80 Mn |
| Jun 30, 2025 | 355.60 Mn |
| Mar 31, 2025 | -217.20 Mn |
| Dec 31, 2024 | 121,000.00 |
| Sep 30, 2024 | -185.02 Mn |
| Jun 30, 2024 | -168.52 Mn |
| Mar 31, 2024 | -21,000.00 |
| Dec 31, 2023 | -136.11 Mn |